Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.
Molecular Weight:
389.49
Purity:
97.97%
CAS Number:
[1401090-53-6]
Formula:
C20H24FN3O2S
Target:
Transferase
T4473
* VAT and and shipping costs not included. Errors and price changes excepted
